Neurocrine Biosciences
NBIX
#1524
Rank
A$18.12 B
Marketcap
$181.80
Share price
1.62%
Change (1 day)
-10.18%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - Total debt

Total debt on the balance sheet as of December 2024 : A$0.71 Billion

According to Neurocrine Biosciences 's latest financial reports the company's total debt is A$0.71 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Neurocrine Biosciences - Total debt on balance sheet (from 1996 to 2024)

Total debt by year

Year Total debt Change
2023-12-31A$0.62 B62.76%
2022-12-31A$0.38 B-36.4%
2021-12-31A$0.60 B13.29%
2020-12-31A$0.53 B-24.24%
2019-12-31A$0.70 B28.33%
2018-12-31A$0.55 B16.48%
2017-12-31A$0.47 B
2009-12-31A$12.83 M-41.19%
2008-12-31A$21.82 M1183.98%
2007-12-31A$1.69 M-97.5%
2006-12-31A$68.04 M-16.18%
2005-12-31A$81.18 M-4.99%
2004-12-31A$85.45 M74.33%
2003-12-31A$49.01 M248.02%
2002-12-31A$14.08 M26.39%
2001-12-31A$11.14 M60.99%
2000-12-31A$6.92 M46.72%
1999-12-31A$4.71 M-3.71%
1998-12-31A$4.89 M99.5%
1997-12-31A$2.45 M21.93%
1996-12-31A$2.01 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
A$1.05 B 47.76%๐Ÿ‡บ๐Ÿ‡ธ USA
A$11.91 B 1,572.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
A$0.73 M-99.90%๐Ÿ‡บ๐Ÿ‡ธ USA
A$48.72 B 6,737.99%๐Ÿ‡บ๐Ÿ‡ธ USA
A$111.29 B 15,518.33%๐Ÿ‡บ๐Ÿ‡ธ USA
A$104.30 B 14,537.88%๐Ÿ‡บ๐Ÿ‡ธ USA
A$0.97 B 37.41%๐Ÿ‡บ๐Ÿ‡ธ USA
A$29.08 M-95.92%๐Ÿ‡บ๐Ÿ‡ธ USA